Chlorpromazine Use and Dosage for Schizophrenia and Acute Psychosis

Dosing Recommendations

A minimum dose equivalent to 600 mg/day of chlorpromazine is considered therapeutic for treatment-resistant schizophrenia 1

Antipsychotic therapy should be implemented for a period of no less than 4-6 weeks using adequate dosages before efficacy can be determined 2, 3
If no results are apparent after 4-6 weeks, or if side effects are unmanageable, a trial of a different antipsychotic should be undertaken 2
For acutely psychotic and agitated patients, short-term use of benzodiazepines as adjuncts may help stabilize the clinical situation 2
This phase generally occurs after 4-12 weeks if the acute phase is controlled 2
Antipsychotic medication should be maintained as additional improvement may occur over 6-12 months following the acute presentation 2
Gradual dose reduction may be indicated to decrease side effects, including negative symptoms, while carefully monitoring for relapse 2

For patients who do not respond to chlorpromazine, a trial of a different antipsychotic should be considered 2, 3
If a patient fails to respond to two adequate trials of different antipsychotics (at least 4 weeks each at therapeutic doses), clozapine should be considered 3, 4
Clozapine is the only antipsychotic with sufficient research to document its superiority in efficacy for treatment-resistant cases 2
For clozapine, aim for a plasma level of at least 350 ng/mL, with doses potentially increased to achieve plasma concentrations up to 550 ng/mL if response is inadequate 3, 5

When switching antipsychotics, use gradual cross-titration based on the half-life and receptor profile of each medication 3, 4
Depot formulations are not recommended for children with very early-onset schizophrenia 6
For adults with documented chronic psychotic symptoms and poor medication compliance, depot antipsychotics may be considered 6
Monthly physician contact is recommended to adequately monitor symptom course, side effects, and compliance 2

Chlorpromazine carries significant cardiovascular risks, particularly at higher doses, and is associated with QTc prolongation and increased risk of ventricular arrhythmias, with an adjusted odds ratio of 1.45 (95% CI 0.93 to 2.27) for ventricular arrhythmia/sudden cardiac death, according to the European Heart Journal 7
Orthostatic hypotension is common, especially in elderly and debilitated patients, as reported by the Annals of Oncology 8

The American Psychiatric Association recommends obtaining baseline measurements, including BMI, waist circumference, blood pressure, HbA1c or fasting glucose, lipid panel, prolactin, liver function tests, urea and electrolytes, full blood count, and ECG, before starting chlorpromazine treatment, with follow-up monitoring schedules as follows: fasting glucose recheck at 4 weeks, weekly BMI, waist circumference, and blood pressure checks for 6 weeks, and annual repeats of all baseline measures 9
Assess renal function before starting any adjunctive metformin, and consider prophylactic metformin when starting chlorpromazine, starting at 500 mg once daily, increasing to 1 g twice daily maximum 9
Review and minimize anticholinergic burden, as chlorpromazine has high central anticholinergic activity 9, 10

For akathisia, consider dose reduction, switch to quetiapine or olanzapine, or add propranolol 10-30 mg two to three times daily 9
For metabolic side effects, offer lifestyle advice, including healthy diet, physical activity, and tobacco cessation, to all patients 9